First Turn Management’s Vertex Pharmaceuticals VRTX Stock Holding History

First Turn Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-35,222	Closed	-$16.4M	–	45
2024 Q3	$16.4M	Sell	35,222 -15,470	-31%	-$7.43M	2.59%	16
2024 Q2	$23.8M	Sell	50,692 -8,140	-14%	-$3.53M	3.87%	7
2024 Q1	$24.6M	Sell	58,832 -22,851	-28%	-$9.66M	3.68%	10
2023 Q4	$33.2M	Buy	+81,683	New	+$30.2M	4.77%	3

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

First Turn Management's VRTX Position: Q4 2024 in Review

First Turn Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 35,222 shares — an estimated $16.4M sold.

First Turn Management first reported a position in VRTX in Q4 2023 and held it in 4 quarters. The position peaked at $33.2M in Q4 2023. 1,557 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

First Turn Management reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
First Turn Management sold 35,222 Vertex Pharmaceuticals shares in Q4 2024, an estimated $16.4M.
First Turn Management first reported a position in Vertex Pharmaceuticals in Q4 2023 and held it in 4 quarters.
First Turn Management's Vertex Pharmaceuticals position peaked at $33.2M in Q4 2023.
1,557 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on First Turn Management's 13F filing for Q4 2024, filed 14 Feb 2025.